✦ LIBER ✦

Reduced ACTH/cortisol responses to naloxone in men with Parkinson's disease

✍ Scribed by R. Volpi; P. Caffarra; A. Marcato; A. Scaglioni; D. Maestri; R. Delsignore; P. Chiodera; V. Coiro

Publisher: Springer
Year: 1991
Tongue: English
Weight: 412 KB
Volume: 3
Category: Article
ISSN: 1435-1463
DOI: 10.1007/bf02260887

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Restoration of ACTH/cortisol and LH resp

Restoration of ACTH/cortisol and LH responses to naloxone by chronic dopaminergic treatment in Parkinson's disease

✍ R. Volpi; P. Caffarra; A. Scaglioni; D. Maestri; P. Chiodera; V. Coiro 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 628 KB

Lack of ACTH/cortisol and GH responses t

Lack of ACTH/cortisol and GH responses to intravenously-infused substance P in Parkinson's disease

✍ R. Volpi; P. Caffarra; A. Scaglioni; A. Saginario; D. Maestri; S. Vourna; P. P. 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 625 KB

Acute levodopa administration reduces co

Acute levodopa administration reduces cortisol release in patients with Parkinson’s disease

✍ T. Müller; J. Welnic; S. Muhlack 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 97 KB

Cortisol and corticotropin (ACTH) respon

Cortisol and corticotropin (ACTH) responses to corticotropin-releasing hormone (CRH) in Alzheimer's disease (AD)

✍ K. P. Lesch; R. Ihl; R. Rupprecht; L. Frölich; H. M. Schulte; K. Maurer 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 65 KB

Postprandial ghrelin response is reduced

Postprandial ghrelin response is reduced in patients with Parkinson’s disease and idiopathic REM sleep behaviour disorder: a peripheral biomarker for early Parkinson’s disease?

✍ Marcus M. Unger; Jens C. Möller; Katharina Mankel; Karla M. Eggert; Katharina Bo 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 269 KB

Cognitive, psychiatric and motor respons

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

✍ D. Aarsland; M. Hutchinson; J. P. Larsen 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 1 views

## Abstract ## Background Cholinesterase inhibitors with additional nicotinic activity, such as galantamine, may be useful in PD patients with dementia (PDD) since stimulation of nicotinic receptors may prevent the down‐regualation that is likely to accompany cholinesterase inhibition and facilita